SCHEMBL20836952

SCHEMBL20836952

COc1cc(C(C)O)cc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C#N)nn4c3=O)nc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 2/20 0.33
▸ HPGD P15428 3/20 0.33
▸ HTT P42858 3/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ NPY1R P25929 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ NPY2R P49146 1/20 0.33
▸ APAF1 O14727 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CTSA P10619 1/20 0.31
▸ PDE2A O00408 1/20 0.31
▸ KDM5A P29375 2/20 0.30
▸ KDM6B O15054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914035 0.88 MAT2A (0.34) MAT2AHPGDHTTKDM4EALDH1A1
SCHEMBL20914059 0.88 MAT2A (0.33) MAT2AHPGDHTTKDM4EALDH1A1
SCHEMBL20913910 0.87 HPGD (0.33) MAT2AHPGDHTTKDM4EALDH1A1
SCHEMBL20914077 0.86 TNKS (0.37) MAT2AHPGDHTTKDM4EALDH1A1
SCHEMBL20837047 0.81 MAT2A (0.33) MAT2AHPGDHTTMEN1KMT2A
SCHEMBL20913982 0.80 MAT2A (0.34) MAT2AHTTKDM4EHSD17B10MEN1
SCHEMBL20914308 0.80 MAT2A (0.34) MAT2AKDM4EMEN1KMT2APKM
SCHEMBL20913913 0.79 KCNA5 (0.38) HPGDKDM4EALDH1A1HSD17B10MAPT
SCHEMBL20914018 0.79 MAT2A (0.34) MAT2AHTTKDM4EALDH1A1HSD17B10
SCHEMBL20837037 0.78 P2RY6 (0.37) HPGDKDM4EALDH1A1HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 MAT2A 1893/4885HPGD 280/4885HTT 165/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 MAT2A 1893/4885HPGD 280/4885HTT 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback